All In Biotech

Drug Trial Radar · NCT06829771

Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma

Phase Ib/II Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma

Last checked: Nov 19, 2026Latest source record: Jan 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Apr 23, 2025

Primary completion

May 2026

Study completion Dec 2026

Sponsor

Sponsor type
Industry
First posted
Feb 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To explore the efficacy and safety of TQB2825 injection combined immunochemotherapy in subjects with untreated or R/R DLBCL. The efficacy evaluation indicators are objective response rate (ORR), complete response rate (CR rate),progression free survival (PFS), duration of response (DOR) and overall survival(OS). The safety evaluation indicators are dose-limiting toxicity (DLT) , maximum tolerated dose (MTD)and recommended phase II dose (RP2D).

Conditions

  • Diffuse Large B Cell Lymphoma

Interventions

  • TQB2825 injection +R-CHOP regimenDrug

    R-CHOP is a cancer treatment regimen that uses a combination of five drugs to treat non-Hodgkin lymphoma, e.g., Rituximab+Cyclophosphamide+Doxorubicin Hydrochloride+Vincristine+Prednisone (R-CHOP). TQB2825 Injection: TQB2825 is a bispecific antibody targeting the cluster of differentiation 20 (CD20) receptor on tumor cells and the cluster of differentiation 3 (CD3) receptor on T cells. Rituximab: A monoclonal antibody that binds to the CD20 antigen on the surface of B cells. Cyclophosphamide: An alkylating agent that inhibits the synthesis of DNA and proteins in cancer cells. Doxorubicin Hydrochloride: An antineoplastic antibiotic that inhibits the synthesis of DNA and RNA. Vincristine: A microtubule inhibitor that blocks the normal function of microtubules during cell division. Prednisone: A corticosteroid drug with anti-inflammatory, anti-allergic, immunosuppressive, and anti-cancer effects. TQB2825 injection + GemOx (Gemcitabine + Oxaliplatin)

  • TQB2825 injection + GemOxDrug

    TQB2825 Injection: TQB2825 is a bispecific antibody targeting the CD20 receptor on tumor cells and the CD3 receptor on T cells. Gemcitabine: A nucleoside analog that inhibits DNA synthesis. Oxaliplatin: A platinum-based chemotherapy drug that forms cross-links with DNA, inhibiting DNA replication and transcription.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Limited ToxicityTime frame: Baseline to up to two years
  2. Maximum tolerated dose (MTD)Time frame: Baseline to up to two years

Locations

25 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, Anhui, China · Not yet recruiting

  • Maanshan People's Hospital

    Ma’anshan, Anhui, China · Recruiting

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China · Not yet recruiting

  • The Second Affiliated Hospital of Fujian Medical University

    Quanzhou, Fujian, China · Recruiting

  • Gansu Provincial Cancer Hospital

    Lanzhou, Gansu, China · Not yet recruiting

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China · Not yet recruiting

  • Liuzhou People's Hospital

    Liuzhou, Guangxi, China · Not yet recruiting

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China · Not yet recruiting

  • Puyang Oilfield General Hospital

    Puyang, Henan, China · Not yet recruiting

  • Henan Cancer Hospital Affiliated Cancer Hospital of Zhengzhou University

    Zhengzhou, Henan, China · Recruiting

  • Hubei Cancer Hospital

    Wuhan, Hubei, China · Not yet recruiting

  • Jiangsu Provincial People's Hospital

    Nanjing, Jiangsu, China · Not yet recruiting

  • The Affiliated Hospital of Xuzhou Medical University

    Xuzhou, Jiangsu, China · Not yet recruiting

  • Jiangxi Canser Hospital

    Nanchang, Jiangxi, China · Not yet recruiting

  • The First Hospital of Jilin University

    Changchun, Jilin, China · Not yet recruiting

  • The second Hospital of dalian

    Dalian, Liaoning, China · Not yet recruiting

  • Affiliated Cancer Hospital of Shandong First Medical University

    Jinan, Shandong, China · Not yet recruiting

  • Yantai Yuhuangding Hospital

    Yantai, Shandong, China · Not yet recruiting

  • Fudan university shanghai cancer center

    Shanghai, Shanghai Municipality, China · Not yet recruiting

  • The First Affiliated Hospital of Xi'an Jiao Tong University

    Xi'an, Shannxi, China · Not yet recruiting

  • Shanxi Cancer hospital

    Taiyuan, Shanxi, China · Not yet recruiting

  • The Affiliated Hospital of Southwest Medical University

    Luzhou, Sichuan, China · Not yet recruiting

  • People's Hospital of Tianjin (City)

    Tianjin, Tianjin Municipality, China · Not yet recruiting

  • Tianjin Medical University Cancer Hospital

    Tianjin, Tianjin Municipality, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.